References
- 1. J. R. Egerton, D. A. Ostlind and L. S. Blair, Avermectins, new family of potent anthelmintic agents: Efficacy of the Bla component, Antimicrob. Agents Chem. 15 (1979) 372-378; DOI: 10.1128/aac. 15.3.372.
- 2. E. A. Ottesen and W. C. Campbell, Ivermectin in human medicine, J. Antimicrob. Chemoth. 34 (1994) 195-203; DOI: 10.1093/jac/34.2.195.
- 3. V. Manetta and G. R. Watkins, Topical Formulation of Ivermectin for the Treatment of DermatologicalConditions, WO 2004093886; ref. Chem. Abstr. 141 (2004) 384319.
- 4. W. L. Shoop, H. Mrozik and M. H. Fisher, Structure and activity of avermectins and milbemycins in animal health, Vet. Parasitol. 59 (1995) 139-156; DOI: 10.1016/0304-4017(94)00743-V.
- 5. R. W. Burg, B. M. Miller and E. E. Baker, Avermectins, new family of potent anthelmintic agents: Producing organism and fermentation, Antimicrob. Agents Ch. 15 (1979) 361-367; DOI: 10.1128/ AAC.15.3.361.
- 6. M. J. Gliddon, Stabilized Formulations Comprising Moxidectin, Australian Pat. AU 2006100657 A4; ref. Chem. Abstr. 146 (2006) 107451.
- 7. United States Pharmacoepia 33, National Formulary 28, USP Convention, Rockville (MD) 2010.
- 8. D. W. Fink, Ivermectin, in Analytical Profiles of Drug Substances (Ed. F. Klaus), Academic Press, New York 1988, pp. 155-184; DOI: 10.1016/S0099-5428(08)60219-1.
- 9. W. Shoop, Ivermectin, Abamectin and Eprinomectin, in Macrocyclic Lactones in Antiparasitic Therapy (Eds. J. Vercruysse and R. S. Rew), CABI Publishing, Wallingford 2002, pp. 1-11; DOI: 10.1079/ 9780851996172.0000.
- 10. J. V. Pivnichny, B. H. Arisen, F. A. Preiser, J. S. K. Shim and H.Mrozik, Base-catalyzed isomerization of avermectins, J. Agr. Food Chem. 36 (1988) 826-828; DOI: 10.1021/jf00082a039.
- 11. A. Awasthi, M. Razzak, R. Al-Kassas, D. R. Greenwood, J. Harvey and S. Garg, Separation and identification of degradation products in eprinomectin formulation using LC, LTQ FT-MS, H/D exchange and NMR, J. Pharm. Biomed. Anal. 63 (2012) 62-73; DOI: 10.1016/j.jpba.2011.12.030.
- 12. A. Awasthi, M. Razzak, R. Al-Kassas, D. R. Greenwood, J. Harvey and S. Garg, Separation and identification of degradation products in abamectin formulation using LC, LTQ FT-MS, H/D exchange and NMR, Curr. Pharm. Anal. (2012), In press.
- 13. J. D. Stong, J. V. Pivnichny, H. Mrozik and F. S. Waksmunski, Radical-induced oxidation of oxahydrindene (hexahydrobenzofuran) portion of 22,23-dihydroavermectin B(1a): Identification of autooxidation products, J. Pharm. Sci. 81 (1992) 1000-1003; DOI: 10.1002/jps.2600811008.
- 14. M. S. Maynard and H. D. Maynard, HPLC assay for avermectin Bla and its two photoisomers using a photo diode array detector, Bull. Environ. Contam. Toxicol. 43 (1989) 499-504; DOI: 10.1007/ BF01701926.
- 15. L. S. Crouch, W. F. Feely, B. H. Arison, W. J. A. VandenHeuvel, L. F. Colwell, R. A. Stearns, W. F. Kline and P. G. Wislocki, Photodegradation of avermectin B1a thin films on glass, J. Agr. FoodChem. 39 (1991) 1310-1319; DOI: 10.1021/jf00007a024.
- 16. A. Awasthi, M. Razzak, R. Al-Kassas, J. Harvey and S. Garg, An overview on chemical derivatization and stability aspects of selected avermectin derivatives, Chem. Pharm. Bull. 60 (2012) 1-14.
- 17. R. Schmidt, Effect of Solvent on Chemical Reactions and Reactivity, in Handbook of Solvents (Ed. G. Wypych), ChemTec Publishing, Toronto 2001, pp. 737-846.
- 18. International Conference on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products. VICH GL-2, Validation of Analytical Procedures: Methodology, Brussels 1998; http://www.vichsec.org/en/topics.htm#1, last access September 17, 2012.
- 19. S. F. Martin, How to measure pH in mixed and nonaqueous solutions, Today’s Chemist at Work 6 (1995) pp. 39-42.